Bosentan in Treatment of Pulmonary Arterial Hypertension

Key facts

Sponsor

Competence Network for Congenital Heart Defects

Principal Investigator

Ingram Schulze-Neick, MD

German Heart Institute

Intervention

Bosentan administration(drug)

Enrollment

60 enrolled

Eligibility

18 years · All sexes

Timeline

2004 – 2008

Study locations (8)

• Kinderkardiologie Universitätsklinikum Freiburg, Freiburg im Breisgau, Baden-Wurttemberg, Germany
• Deutsches Herzzentrum Muenchen, Munich, Bavaria, Germany
• Universitätsklinikum Giessen and Marburg, Giessen, Hesse, Germany
• Herz-und Diabeteszentrum NRW, Bad Oeynhausen, North Rhine-Westphalia, Germany
• Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, North Rhine-Westphalia, Germany
• Universitätsklinikum des Saarlandes, Homburg, Saarland, Germany
• Universitätsklinikum der Martin-Luther-Universität Halle-Wittenberg, Halle, Saxony-Anhalt, Germany
• Deutsches Herzzentrum Berlin, Berlin, State of Berlin, Germany

Collaborators

German Federal Ministry of Education and Research · Actelion

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Eisenmenger syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE4NCT07356778
  A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy
  Kazuya Hosokawa
• RECRUITINGNANCT05611268
  Pentoxifylline as an Adjunct Therapy for Patients With Eisenmenger Syndrome
  University of Sao Paulo General Hospital

See all trials for Eisenmenger syndrome →